tetano
Editor, Senior Moderator
J Virol. 2013 Jan 2. [Epub ahead of print]
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza in ferrets immunised with seasonal influenza vaccine.
Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D.
Source
CSL Limited, 45 Poplar Rd Parkville, Victoria, Australia.
Abstract
In preparing for the threat of a pandemic of avian H5N1 influenza virus we need to consider the significant delay (4-6 months) necessary to produce a strain-matched vaccine. As some degree of cross-reactivity between seasonal influenza vaccines and H5N1 virus has been reported, this was further explored in the ferret model to determine the targets of protective immunity. Ferrets were vaccinated with two intramuscular inoculations of trivalent inactivated split influenza vaccine or sub-component vaccines, with and without adjuvant, and later challenged with a lethal dose of A/Vietnam/1203/2004 (H5N1) influenza virus. We confirmed that vaccination with seasonal influenza vaccine afforded partial protection against lethal H5N1 challenge and showed that use of either AlPO(4) or ISCOMATRIX? adjuvant with the vaccine resulted in complete protection against disease and death. The protection was due exclusively to the H1N1 vaccine component, and although the hemagglutinin contributed to protection, the dominant protective response was targeted towards the neuraminidase (NA) and correlated with sialic acid cleavage-inhibiting antibody titres. Purified heterologous NA formulated with ISCOMATRIX? adjuvant was also protective. These results suggest that adjuvanted seasonal trivalent vaccine could be used as an interim measure to decrease morbidity and mortality from H5N1 prior to the availability of specific vaccine. The data also suggests NA as an inducer of cross-protective immunity, a protein whose levels are not normally monitored in vaccines and whose capacity to induce immunity in recipients is not normally assessed.
PMID:
23283953
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23283953
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza in ferrets immunised with seasonal influenza vaccine.
Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D.
Source
CSL Limited, 45 Poplar Rd Parkville, Victoria, Australia.
Abstract
In preparing for the threat of a pandemic of avian H5N1 influenza virus we need to consider the significant delay (4-6 months) necessary to produce a strain-matched vaccine. As some degree of cross-reactivity between seasonal influenza vaccines and H5N1 virus has been reported, this was further explored in the ferret model to determine the targets of protective immunity. Ferrets were vaccinated with two intramuscular inoculations of trivalent inactivated split influenza vaccine or sub-component vaccines, with and without adjuvant, and later challenged with a lethal dose of A/Vietnam/1203/2004 (H5N1) influenza virus. We confirmed that vaccination with seasonal influenza vaccine afforded partial protection against lethal H5N1 challenge and showed that use of either AlPO(4) or ISCOMATRIX? adjuvant with the vaccine resulted in complete protection against disease and death. The protection was due exclusively to the H1N1 vaccine component, and although the hemagglutinin contributed to protection, the dominant protective response was targeted towards the neuraminidase (NA) and correlated with sialic acid cleavage-inhibiting antibody titres. Purified heterologous NA formulated with ISCOMATRIX? adjuvant was also protective. These results suggest that adjuvanted seasonal trivalent vaccine could be used as an interim measure to decrease morbidity and mortality from H5N1 prior to the availability of specific vaccine. The data also suggests NA as an inducer of cross-protective immunity, a protein whose levels are not normally monitored in vaccines and whose capacity to induce immunity in recipients is not normally assessed.
PMID:
23283953
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23283953